McKesson Corporation (LON:0JZU)
United Kingdom · Delayed Price · Currency is GBP · Price in USD | Market Cap | 93.33B +16.8% |
| Revenue (ttm) | 315.45B +8.2% |
| Net Income | 3.54B +16.5% |
| EPS | 29.36 +21.3% |
| Shares Out | n/a |
| PE Ratio | 27.42 |
| Forward PE | 21.99 |
| Dividend | 2.83 (0.35%) |
| Ex-Dividend Date | Dec 1, 2026 |
| Volume | 71 |
| Open | 1,068.83 |
| Previous Close | 1,075.77 |
| Day's Range | 1,046.00 - 1,089.74 |
| 52-Week Range | 710.01 - 1,116.60 |
| Beta | 0.28 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 4, 2026 |
About McKesson
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products; delivers products to retail pharmacies, hospitals, long-term care centers, clinics, and institutions; and provides logistics and distribution services f... [Read more]
Financial Performance
In fiscal year 2026, McKesson's revenue was $403.43 billion, an increase of 12.36% compared to the previous year's $359.05 billion. Earnings were $4.76 billion, an increase of 44.52%.
Financial numbers in USD Financial StatementsNews
Sales of Pharmaceuticals, GLP-1s Send McKesson Shares to New Highs
McKesson Corporation (MCK) shares up over 235% since May 2022 thanks to institutional support.
McKesson price target raised to $1,255 from $1,042 at JPMorgan
JPMorgan raised the firm’s price target on McKesson (MCK) to $1,255 from $1,042 and keeps an Overweight rating on the shares.
McKesson price target raised to $1,260 from $1,207 at Morgan Stanley
Morgan Stanley raised the firm’s price target on McKesson (MCK) to $1,260 from $1,207 and keeps an Overweight rating on the shares.
McKesson price target raised to $1,050 from $1,020 at Mizuho
Mizuho raised the firm’s price target on McKesson (MCK) to $1,050 from $1,020 and keeps a Neutral rating on the shares.
McKesson price target raised to $1,250 from $1,050 at BofA
BofA raised the firm’s price target on McKesson (MCK) to $1,250 from $1,050 and keeps a Buy rating on the shares after the company reported a fiscal Q2 EPS beat.
McKesson price target raised to $965 from $845 at RBC Capital
RBC Capital raised the firm’s price target on McKesson (MCK) to $965 from $845 and keeps a Sector Perform rating on the shares. The company reported a broad based beat…
McKesson price target raised to $1,200 from $1,006 at TD Cowen
TD Cowen raised the firm’s price target on McKesson (MCK) to $1,200 from $1,006 and keeps a Buy rating on the shares. The firm said their results were driven by…
McKesson price target raised to $1,250 from $1,200 at UBS
UBS raised the firm’s price target on McKesson (MCK) to $1,250 from $1,200 and keeps a Buy rating on the shares.
McKesson price target raised to $1,200 from $1,000 at Evercore ISI
Evercore ISI analyst Elizabeth Anderson raised the firm’s price target on McKesson (MCK) to $1,200 from $1,000 and keeps an Outperform rating on the shares.
McKesson price target raised to $1,225 from $1,017 at Baird
Baird raised the firm’s price target on McKesson (MCK) to $1,225 from $1,017 and keeps an Outperform rating on the shares. The firm updated its model following quarterly results. Published…
McKesson reports Q2 adjusted EPS $11.68, consensus $10.75
Reports Q2 revenue $111B, consensus $109.95B. “McKesson (MCK) delivered another quarter of strong results, reflecting operational strength in our core business segments and disciplined execution acros...
McKesson raises FY27 EPS view to $45.60-$46.40 from $44.20-$45
Consensus $44.66.
McKesson Earnings Call Transcript: Q2 2027
Q2 revenue rose 8% and adjusted EPS grew 18% to $11.68, prompting higher FY27 guidance. Growth spanned all segments, alongside strategic expansion through PMG and a planned Option Care investment.
McKesson Earnings release: Q2 2027
McKesson released its Q2 2027 earnings on November 4, 2026, summarizing the period's financial results.
McKesson Slides: Q2 2027
McKesson has posted slides in relation to its Q2 2027 quarterly earnings report, which was published on November 4, 2026.
McKesson Quarterly report: Q2 2027
McKesson has published its Q2 2027 quarterly earnings report on November 4, 2026.
McKesson Reports Fiscal 2027 Second Quarter Results and Raises Full Year Adjusted EPS Guidance
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) has released its fiscal 2027 second quarter financial results. Results can be accessed on McKesson's Investor Relations website at inve...
McKesson price target raised to $1,207 from $977 at Morgan Stanley
Morgan Stanley analyst Erin Wright raised the firm’s price target on McKesson (MCK) to $1,207 from $977 and keeps an Overweight rating on the shares.
Cardinal Health, McKesson awarded $2.7B and $741.5M DLA contracts respectively
Cardinal Health (CAH) and McKesson (MCK) have each been awarded fixed-price, indefinite-delivery/indefinite-quantity contracts worth $2.7B and $741.5M respectively under a solicitation for the Medical...
McKesson Corporation Declares Quarterly Dividend
IRVING, Texas--(BUSINESS WIRE)--The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of 94 cents per share of common stock. The dividend will be payable on J...
McKesson price target raised to $1,020 from $905 at Mizuho
Mizuho raised the firm’s price target on McKesson (MCK) to $1,020 from $905 and keeps a Neutral rating on the shares. The firm adjusted targets in the drug distributor space…
McKesson price target raised to $1,200 from $1,080 at UBS
UBS raised the firm’s price target on McKesson (MCK) to $1,200 from $1,080 and keeps a Buy rating on the shares.
CD&R, McKesson to Acquire At-Home Infusion Therapy Provider for $5.8 Billion
Under the agreement, CD&R will hold a majority interest of about 51% in Option Care Health, while McKesson will hold about 49%.
McKesson, CD&R to take infusion therapy provider Option Care private in $5.8 billion deal
Drug distributor McKesson and private equity firm Clayton Dubilier & Rice on Tuesday agreed to take infusion therapy provider Option Care Health private in a deal worth about $5.8 billion including ...